Eisai Co., Ltd. produces prescription drugs and medical equipment and sells mainly to sales agents and subsidiaries.  Through its subsidiary, Sanko Junyaku, the Company produces and sells diagnostic drugs.  Eisai also markets its products through related companies in the US, Europe, and Asia.  The Company also manufactures and sells foods, livestock feeds, chemical, and agrochemicals.

Revenue Of Leqembi (Preliminary Basis)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eisai Co Ltd (4523 JP)

Revenue Of Leqembi (Preliminary Basis)

Eisai Announces Status And Completion Of Acquisition Of Own Shares

Eisai Announces Status Relating To Acquisition Of Own Shares

Eisai Announces Status Relating To Acquisition Of Own Shares

Leqembi (Lecanemab) Authorized For Early Alzheimer’S Disease In Great Britain

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)